Dr. Ming Yang is the Founder, President, and CEO of Bright Biologics LLC, bringing over 20 years of experience in biopharmaceutical research and development, with deep expertise in antibody engineering and therapeutic antibody discovery.

Prior to founding Bright Biologics, Dr. Yang served as Group Leader of Cell Biology at Hengenix Biotech, where he established an in vitro cell-based screening platform for oncology antibody drug discovery. He led multiple antibody programs, including VHH and bispecific antibodies, with a strong emphasis on antibody engineering. His work in affinity optimization, Fc engineering, and functional enhancement drove the successful advancement of several lead candidates into IND-enabling studies and Phase I clinical trials.

Earlier in his career, Dr. Yang was a Senior Scientist at Gilead, where he led an in vitro cell-based assay group supporting drug discovery and screening.

Dr. Yang earned his MD in China, where he practiced medicine, and later obtained a doctorate in Molecular Pharmacology in Germany. He completed postdoctoral training in Molecular Immunology at the University of Illinois at Chicago and in Molecular Oncology at Amgen.

He is the first inventor on eight antibody-related patent applications, seven of which focus on bispecific antibodies, highlighting his specialization in advanced antibody engineering. He has authored or co-authored more than 30 peer-reviewed publications, serving as first or corresponding author on 13. His multidisciplinary expertise in clinical medicine, cell and molecular biology, and antibody engineering provides a strong strategic foundation for the company’s R&D.